Panvascular-JEPA: Unseen-Structure Evaluation of Factorized Predictive States for Hemodynamic Networks

Abstract

Predictive representations for vascular simulation should be tested on unseen network structures and compared with the governing equations before being interpreted as general-purpose world models. We constructed a new, dimensioned but uncalibrated nodal resistance-inertance-compliance benchmark containing all 38 connected, non-isomorphic six-node graphs with five to seven edges. Twenty-four structures supplied training, validation, and new-background testing; 14 structures were wholly withheld. Across 648 parameter backgrounds and two prescribed action programs, 1,296 trajectories contained 96 forecast steps over three cycles. Four graph predictors received equal six candidate optimization searches, followed by five fixed-seed fits. Selected configurations and analysis code were locked before test trajectories were generated. Comparators included known-equation numerical integrators, an inertia-free reduction, and a five-coefficient model fitted to training trajectories. Unseen-structure mean standardized RMSE was 8.46 × 10 9 for four-factor OPF, 329 for single factor OPF, and 1.83 × 10 31 for supervised graph prediction, compared with 1.09 × 10 -4 for foursubstep known-equation integration and 6.77 × 10 4 for the fitted mechanism. The primary OPF-4 minus OPF-1 difference was 8.46 × 10 9 , with a paired stratified-graph 95% percentile interval of [2.23 × 10 5 , 2.54 × 10 10 ]. Neural errors were strongly dependent on training seed and network structure, with extreme forecasts dominating the means. All four neural means exceeded persistence; relative performance within this comparison did not establish a usable forecasting model. The study supplies a distinct numerical test of structure transfer, factor-count control, and recursive stability. Its conclusions concern the implemented models, optimization budget, and finite graph catalogue. It establishes neither patient-specific performance nor anatomical transfer, biological remodeling, device efficacy, or clinical readiness.